Volume 6, Issue 4 (Nov 2018)                   Res Mol Med (RMM) 2018, 6(4): 20-27 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Fotoohi M, Hadi N, Namazi F. Effect of Foretinib on Matrix Metalloproteinase-2 (MMP2) Expression in Glioblastoma. Res Mol Med (RMM). 2018; 6 (4) :20-27
Abstract:   (1225 Views)
Background: The most malignant form of infiltrating astrocytoma, glioblastoma multiforme (GBM), is one of the most aggressive human cancers. Foretinib diminished GBM cell invasion by downregulating the expression of matrix metalloproteinase 2 (MMP2). The study aimed to examine the anti-tumor activity of foretinib and to test its effect on MMP2 expression in T98 cells.
Materials and methods: T98 cells were used as an experimental model of glioblastoma. The effect of foretinib on the expression of MMP2 was evaluated using quantitative real-time polymerase chain reaction. Thereafter, the effect of foretinib on the enzyme levels of MMP was examined by zymography. Statistical analyses were performed with GraphPad Prism software.
Results: A reduction in the expression of MMP2 was observed with an increase in the concentration of foretinib.
Conclusion: Foretinib treatment leads to downregulation of MMP-2 and has a positive effect on T98 cells. We believe that foretinib can be subjected to further clinical investigation to develop a treatment for GBM.
Full-Text [PDF 314 kb]   (339 Downloads)    
Type of Study: Research | Subject: Genetic
Received: 2019/04/21 | Published: 2018/11/15

Add your comments about this article : Your username or Email:

Send email to the article author

© 2021 All Rights Reserved | Research in Molecular Medicine

Designed & Developed by : Yektaweb